Catalyst

Slingshot members are tracking this event:

Aduro Biotech (ADRO) is set to initiate CRS-207 and aPD-1 combination trial, testing pair as treatment of mesothelioma, in second half of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ADRO Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 28, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Crs-207, Apd-1, Mesothelioma